Lennart Conemans

Lennart Conemans

Auto-generated profile, based on publicly available information

Lennart Conemans

NUTRIM, Institute for Nutrition and Translational Research in Metabolism Maastricht University Maastricht the Netherlands

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2017 in Blood
Verified
Journal Article
Closed access
PDF file
TTTamar Tak
Tamar Tak
JDJulia Drylewicz
Julia Drylewicz
LCLennart Conemans
Lennart Conemans
RBRob De Boer
Rob De Boer
Leo KoendermanLeo Koenderman
Leo Koenderman
KTKiki Tesselaar
Kiki Tesselaar
To the editor: Monocytes originate from the bone marrow (BM), are distributed in the bloodstream, and can differentiate in the tissue into skin macrophages or intestinal dendritic cells (DCs).[1][1] They play an essential role in the defense against pathogens[2][2] and are implicated in a range of

1 February 2021 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
GTGörkem Türkkan
Görkem Türkkan
YWYves Willems
Yves Willems
LHLizza E.L. Hendriks
Lizza E.L. Hendriks
RMRémy Mostard
Rémy Mostard
LCLennart Conemans
Lennart Conemans
DRDirk De Ruysscher
Dirk De Ruysscher

6 August 2024 in Journal of Medical Internet Research
Verified
Journal Article
Open access
MOMartinus C Oppelaar
Martinus C Oppelaar
YEYvette Emond
Yvette Emond
MBMichiel A.G.E. Bannier
Michiel A.G.E. Bannier
MRMonique Reijers
Monique Reijers
HVHester van der Vaart
Hester van der Vaart
JRJ Roukema
J Roukema
Background: The current literature inadequately addresses the extent to which remote monitoring should be integrated into care models for chronic respiratory diseases (CRDs). Objective: This study examined a remote monitoring program (RMP) in cystic fibrosis (CF) by exploring experiences, future perspectives, and use behavior over 3 years, with the aim of developing future directions for remote monitoring in CRDs. Methods: This was a mixed methods, multicenter, observational study in 5 Dutch CF centers following a sequential explanatory design. Self-designed questionnaires using the technology acceptance model were sent out to people with CF who had a minimum of 12 months of experience with the RMP and local health care professionals (HCPs). Questionnaire outcomes were used to inform semistructured interviews with HCPs and people with CF. Qualitative findings were reported following the COREQ (Consolidated Criteria for Reporting Qualitative Research) checklist. Anonymous data on use frequency of all people with CF were analyzed. Results: Between the second quarter of 2020 and the end of 2022, a total of 608 people with CF were enrolled in the program, and a total of 9418 lung function tests and 2631 symptom surveys were conducted. In total, 65% (24/37) of HCPs and 89% (72/81) of people with CF responded to the questionnaire, and 7 HCPs and 12 people with CF participated in semistructured interviews. Both people with CF and HCPs were positive about remote monitoring in CF care and found the RMP a good addition to daily care (people with CF: 44/72, 61%; HCPs: 21/24, 88%). Benefits ranged from supporting individual patients to reducing health care consumption. The most valued monitoring tool was home spirometry by both people with CF (66/72, 92%) and HCPs (22/24, 92%). Downsides included the potential to lose sight of patients and negative psychosocial effects, as 17% (12/72) of people with CF experienced some form of stress due to the RMP. A large majority of people with CF (59/72, 82%) and HCPs (22/24, 92%) wanted to keep using the RMP in future, with 79% (19/24) of HCPs and 75% (54/72) of people with CF looking forward to more replacement of in-person care with digital care during periods of well-being. Future perspectives for the RMP were centered on creating hybrid care models, personalizing remote care, and balancing individual benefits with monitoring burden. Conclusions: Remote monitoring has considerable potential in supporting people with CF and HCPs within the CF care model. We identified 4 practice-based future directions for remote monitoring in CF and CRD care. The strategies, ranging from patient driven to prediction driven, can help clinicians, researchers, and policy makers navigate the rapidly changing digital health field, integrate remote monitoring into local care models, and align remote care with patient and clinician needs.

3 December 2024 in Journal of Medical Internet Research
Verified
Journal Article
Open access
MOMartinus C Oppelaar
Martinus C Oppelaar
HHHanneke Ac van Helvoort
Hanneke Ac van Helvoort
MBMichiel A.G.E. Bannier
Michiel A.G.E. Bannier
MRMonique Reijers
Monique Reijers
HVHester van der Vaart
Hester van der Vaart
JRJ Roukema
J Roukema
Background: Portable spirometers are increasingly used to measure lung function at home, but doubts about the accuracy of these devices persist. These doubts stand in the way of the digital transition of chronic respiratory disease care, hence there is a need to address the accuracy of home spirometry in routine care across multiple settings and ages. Objective: This study aimed to assess the accuracy, reproducibility, and responsiveness to the treatment of home spirometry in long-term pediatric and adult cystic fibrosis care. Methods: This retrospective observational study was carried out in 5 Dutch cystic fibrosis centers. Home spirometry outcomes (forced expiratory volume in one second [FEV1], and forced vital capacity [FVC]) for 601 anonymized users were collected during 3 years. For 81 users, data on clinic spirometry and elexacaftor/tezacaftor/ivacaftor (ETI) use were available. Accuracy was assessed using Bland-Altman plots for paired clinic-home measurements on the same day and within 7 days of each other (nearest neighbor). Intratest reproducibility was assessed using the American Thoracic Society/European Respiratory Society repeatability criteria, the coefficient of variation, and spirometry quality grades. Responsiveness was measured by the percentage change in home spirometry outcomes after the start of ETI. Results: Bland-Altman analysis was performed for 86 same-day clinic-home spirometry pairs and for 263 nearest neighbor clinic-home spirometry pairs (n=81). For both sets and for both FEV1 and FVC, no heteroscedasticity was present and hence the mean bias was expressed as an absolute value. Overall, home spirometry was significantly lower than clinic spirometry (mean ΔFEV1clinic-home 0.13 L, 95% CI 0.10 to 0.19; mean ΔFVCclinic-home 0.20 L, 95% CI 0.14 to 0.25) and remained lower than clinic spirometry independent of age and experience. One-way ANOVA with post hoc comparisons showed significantly lower differences in clinic-home spirometry in adults than in children (Δmean 0.11, 95% CI –0.20 to –0.01) and teenagers (Δmean 0.14, 95% CI –0.25 to –0.02). For reproducibility analyses, 2669 unique measurement days of 311 individuals were included. Overall, 87.3% (2331/2669) of FEV1 measurements and 74.3% (1985/2669) of FVC measurements met reproducibility criteria. Kruskal-Wallis with pairwise comparison demonstrated that for both FVC and FEV1, coefficient of variation was significantly lower in adults than in children and teenagers. A total of 5104 unique home measurements were graded. Grade E was given to 2435 tests as only one home measurement was performed. Of the remaining 2669 tests, 43.8% (1168/2669) and 43.6% (1163/2669) received grade A and B, respectively. The median percentage change in FEV1 from baseline after initiation of ETI was 19.2% after 7-14 days and remained stable thereafter (n=33). Conclusions: Home spirometry is feasible but not equal to clinic spirometry. Home spirometry can confirm whether lung functions remain stable, but the context of measurement and personal trends are more relevant than absolute outcomes.

9 January 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
PBPia Bertram
Pia Bertram
MOMartinus C Oppelaar
Martinus C Oppelaar
MBMichiel A.G.E. Bannier
Michiel A.G.E. Bannier
MRMonique Reijers
Monique Reijers
HVHester van der Vaart
Hester van der Vaart
JRJ Roukema
J Roukema
Background: Home spirometers have been widely implemented in the treatment of people with cystic fibrosis (CF). Frequent spirometry measurements at home could lead to earlier detection of exacerbations. However, previous research indicates that the long-term use of home spirometry is not well maintained by people with CF. Objective: We aimed to gain insight into the long-term uptake of home spirometry in regular multicenter CF care. Methods: Home spirometers combined with a remote monitoring platform were introduced in the treatment of people with CF in 5 Dutch CF centers starting in April 2020. Usage data from April 2020 to December 2022 were analyzed retrospectively. Survival analyses were conducted to assess use consistency over time, and t tests were used to evaluate the impact of increased pulmonary symptoms on home spirometry frequency. The effect of the initiation of a new treatment, Elexacaftor/Tezacaftor/Ivacaftor, on use frequency over time was assessed in a subgroup of participants with repeated measures ANOVA. Results: During the observation period, a total of 604 people with CF were enrolled in the remote monitoring platform and 9930 home spirometry measurements were performed. After the initiation of home spirometry use, the number of users declined rapidly. One year after the initiation, 232 (54.2%) people with CF stopped using home spirometry. During the observation period, 67 (11.1%) users performed more than 20 measurements. Furthermore, the number of consistent home spirometry users decreased over time. After 600 days, only 1% of users had measured their lung function consistently every 31 days. Use frequency slightly increased during periods with increased pulmonary symptoms (ΔMean=0.45, t497.278=–4,197; P<.001) and showed an initial rise followed by a decrease after starting treatment with Elexacaftor/Tezacaftor/Ivacaftor (ΔMean=0.45, t497.278=–4,197; P<.001). Conclusions: Consistent uptake of home spirometry in people with CF is low but increases around periods of changing symptoms. A clear strategy for the organization of remote care seemed to improve the long-term uptake of home spirometry. Nevertheless, home spirometry and its intensity are not a goal on their own but should be used as a tool to reach individual goals within local contexts.

12 March 2025 in Respirology Case Reports
Verified
Journal Article
Open access
LCLennart Conemans
Lennart Conemans
EDEmel Demir
Emel Demir
MBMartijn Bischoff
Martijn Bischoff
FFFrits Franssen
Frits Franssen
SSSami Simons
Sami Simons
Asthma exacerbations remain life‐threatening events despite advancements in biologic therapies. This case series reports on four patients with near‐fatal eosinophilic asthma exacerbations who had been admitted to intensive care and were treated with benralizumab as a last resort after failing maximal standard therapies. All patients exhibited marked blood or airway eosinophilia and required intensive care ventilatory support. Following the administration of benralizumab, significant clinical improvements were observed. This series highlights the potential role of benralizumab in treating life‐threatening asthma exacerbations driven by eosinophilic airway inflammation and underlines the need for phenotyping and timely intervention in managing such patients with near‐fatal asthma while also stressing the need for continued adherence to asthma guidelines to prevent these extreme situations.